GABAA Modulators for Histamine-Independent Itch Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for itch and dermatitis often rely on H1-antihistamines, which are ineffective for histamine-independent cases, and other medications can have significant side effects, highlighting a need for alternative pharmaceutical compounds that effectively target itch and dermatitis without these limitations.

Innovation Solution

Administration of GABAA modulating compounds, such as PF-06372865, SL65.1498, AZD7325, and AZD6280, in various pharmaceutical compositions, including oral, rectal, and parenteral forms, to provide a therapeutically effective amount for treating or preventing itch and dermatitis, potentially combined with emulsifying agents, penetration enhancers, and suspending agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If H1-antihistamines are used to treat itch, then histamine-related itch is effectively treated, but histamine-independent itch cases remain untreated

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidapplicability to different itch types

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent transitions from targeting histamine receptors (H1-antihistamines) to targeting GABA receptors, changing the pharmacological parameter of the treatment approach. This allows the same treatment mechanism to address multiple types of itch regardless of their underlying cause, resolving the limitation of H1-antihistamines being effective only for histamine-related itch

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

GABA receptor modulators are proposed as a universal treatment for both histamine-dependent and histamine-independent itch, making the treatment applicable across different itch etiologies. This multi-functional approach eliminates the need to differentiate between itch types for treatment selection

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If conventional medications are used to treat itch and dermatitis, then symptom relief is achieved, but significant side effects occur

Engineering Contradiction:

Improvesymptom reliefVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the itch-relieving function from conventional medications that cause side effects and isolates it in a new class of GABA receptor modulators. By targeting a different receptor system (GABA instead of histamine or other pathways), the treatment achieves symptom relief without the harmful side effects associated with conventional medications

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

GABA receptor modulators serve as an intermediary mechanism between the cause of itch and the symptom expression. By acting on GABA receptors in the nervous system, these compounds provide a indirect but effective pathway to relieve itch symptoms without directly interfering with the underlying pathological processes that cause side effects in conventional treatments

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS11571421B2GABAA positive allosteric modulator compounds for treatment of itch and/or dermatitis

Publication Date: 2023.02.07 NEUROCYCLE THERAPEUTICS INC

AI summary

Disclosed herein are GABAA positive allosteric modulators for the treatment of pruritic conditions and dermatitis. Also disclosed herein are formulations comprising the GABAA positive allosteric modulators.